PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a (177)Lu-labeled αPD-L1 antibody

Rationale: The low response rate of immunotherapy, such as anti-PD-L1/PD-1 and anti-CTLA4, has limited its application to a wider population of cancer patients. One widely accepted view is that inflammation within the tumor microenvironment is low or ineffective for inducing the sufficient infiltrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jingyun, Xu, Mengxin, Chen, Junyi, Ding, Jie, Wang, Peipei, Huo, Li, Li, Fang, Liu, Zhibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681088/
https://www.ncbi.nlm.nih.gov/pubmed/33391476
http://dx.doi.org/10.7150/thno.45540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681088/
https://www.ncbi.nlm.nih.gov/pubmed/33391476
http://dx.doi.org/10.7150/thno.45540

Ejemplares similares